Prokidney Corp Stock Analysis
| PROK Stock | USD 1.85 0.03 1.60% |
ProKidney Corp is undervalued with Real Value of 5.16 and Target Price of 15.33. The main objective of ProKidney Corp stock analysis is to determine its intrinsic value, which is an estimate of what ProKidney Corp is worth, separate from its market price. There are two main types of ProKidney Corp's stock analysis: fundamental analysis and technical analysis.
The ProKidney Corp stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
ProKidney |
ProKidney Stock Analysis Notes
About 27.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.54. ProKidney Corp had not issued any dividends in recent years. The entity had 1:1 split on the 12th of July 2022. ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina. Prokidney Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about ProKidney Corp contact Bruce MD at 336 999 7028 or learn more at https://www.prokidney.com.ProKidney Corp Investment Alerts
| ProKidney Corp generated a negative expected return over the last 90 days | |
| ProKidney Corp has high historical volatility and very poor performance | |
| ProKidney Corp may become a speculative penny stock | |
| ProKidney Corp has high likelihood to experience some financial distress in the next 2 years | |
| ProKidney Corp currently holds 4.41 M in liabilities with Debt to Equity (D/E) ratio of 5.66, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ProKidney Corp has a current ratio of 0.73, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about ProKidney Corp's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (135.45 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ProKidney Corp currently holds about 21.88 M in cash with (90.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36. | |
| ProKidney Corp has a very weak financial position based on the latest SEC disclosures | |
| Roughly 27.0% of ProKidney Corp outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: ProKidney to Participate in Two Upcoming Conferences Evercore HealthCONx Conference and the Citi Global Healthcare Conference |
ProKidney Corp Upcoming and Recent Events
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ProKidney Largest EPS Surprises
Earnings surprises can significantly impact ProKidney Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-10 | 2024-03-31 | -0.18 | -0.16 | 0.02 | 11 | ||
2023-11-14 | 2023-09-30 | -0.16 | -0.18 | -0.02 | 12 | ||
2024-03-22 | 2023-12-31 | -0.17 | -0.09 | 0.08 | 47 |
ProKidney Stock Institutional Investors
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 288 K | Bank Of New York Mellon Corp | 2024-06-30 | 179.2 K | Alps Advisors Inc | 2024-09-30 | 97.4 K | Millennium Management Llc | 2024-06-30 | 91.9 K | Alliancebernstein L.p. | 2024-06-30 | 84.2 K | Rhumbline Advisers | 2024-06-30 | 76.2 K | Citigroup Inc | 2024-09-30 | 75.2 K | Metlife Investment Management, Llc | 2024-09-30 | 62.7 K | Mariner Wealth Advisors Llc | 2024-06-30 | 51.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 28.9 M | Suvretta Capital Management, Llc | 2024-06-30 | 9.3 M |
ProKidney Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.81 B.ProKidney Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.08) | (0.09) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.08) | (0.09) | |
| Return On Equity | 0.03 | 0.03 |
Management Efficiency
ProKidney Corp has return on total asset (ROA) of (0.2037) % which means that it has lost $0.2037 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3134) %, meaning that it created substantial loss on money invested by shareholders. ProKidney Corp's management efficiency ratios could be used to measure how well ProKidney Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 0.03 this year, although the value of Return On Tangible Assets will most likely fall to (0.09). Total Current Liabilities is expected to rise to about 26.3 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 223.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.34 | 6.66 | |
| Tangible Book Value Per Share | 6.34 | 6.66 | |
| Enterprise Value Over EBITDA | (0.36) | (0.38) | |
| Price Book Value Ratio | (0.10) | (0.09) | |
| Enterprise Value Multiple | (0.36) | (0.38) | |
| Price Fair Value | (0.10) | (0.09) | |
| Enterprise Value | -59.1 M | -62.1 M |
The management team at ProKidney Corp has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 1.305 | Return On Assets (0.20) | Return On Equity (0.31) |
Technical Drivers
As of the 28th of November, ProKidney Corp holds the Variance of 37.2, insignificant risk adjusted performance, and Coefficient Of Variation of (7,494). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProKidney Corp, as well as the relationship between them.ProKidney Corp Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ProKidney Corp middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ProKidney Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ProKidney Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProKidney Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProKidney Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProKidney Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ProKidney Corp Predictive Daily Indicators
ProKidney Corp intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ProKidney Corp stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ProKidney Corp Forecast Models
ProKidney Corp's time-series forecasting models are one of many ProKidney Corp's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProKidney Corp's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ProKidney Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ProKidney Corp prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ProKidney shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ProKidney Corp. By using and applying ProKidney Stock analysis, traders can create a robust methodology for identifying ProKidney entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current ProKidney Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ProKidney analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ProKidney analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 15.33 | Buy | 8 | Odds |
Most ProKidney analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ProKidney stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ProKidney Corp, talking to its executives and customers, or listening to ProKidney conference calls.
ProKidney Stock Analysis Indicators
ProKidney Corp stock analysis indicators help investors evaluate how ProKidney Corp stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ProKidney Corp shares will generate the highest return on investment. By understating and applying ProKidney Corp stock analysis, traders can identify ProKidney Corp position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 490.3 M | |
| Total Stockholder Equity | -1.1 B | |
| Capital Lease Obligations | 4.4 M | |
| Property Plant And Equipment Net | 46.4 M | |
| Cash And Short Term Investments | 362.9 M | |
| Net Invested Capital | -1.1 B | |
| Cash | 60.6 M | |
| 50 Day M A | 1.8526 | |
| Net Interest Income | 21.2 M | |
| Total Current Liabilities | 25 M | |
| Investments | -234.4 M | |
| Interest Expense | 12 K | |
| Stock Based Compensation | 30.8 M | |
| Common Stock Shares Outstanding | 61.7 M | |
| Tax Provision | 1.9 M | |
| Free Cash Flow | -124.3 M | |
| Operating Income | -151.5 M | |
| Other Current Assets | 9.8 M | |
| Accounts Payable | 5.1 M | |
| Net Debt | -56.2 M | |
| Depreciation | 3.9 M | |
| Other Operating Expenses | 151.5 M | |
| Non Current Assets Total | 46.4 M | |
| Liabilities And Stockholders Equity | 420.6 M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProKidney Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Return On Assets (0.20) | Return On Equity (0.31) |
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.